PMID- 37058160
OWN - NLM
STAT- MEDLINE
DCOM- 20230626
LR  - 20230701
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Print)
IS  - 0940-5429 (Linking)
VI  - 60
IP  - 8
DP  - 2023 Aug
TI  - Microbiota-gut-brain axis: relationships among the vagus nerve, gut microbiota, 
      obesity, and diabetes.
PG  - 1007-1017
LID - 10.1007/s00592-023-02088-x [doi]
AB  - AIMS: The purpose of this review is to explore the interconnected pathways of the 
      microbiota-gut-brain axis (MGBA), focusing on the roles of the vagus nerve and 
      glucagon like peptide-1 in appetite control, and in the development of obesity 
      and diabetes. METHODS: Type 2 diabetes mellitus (T2DM) and obesity are metabolic 
      disorders whose prevalence has significantly increased in recent decades and is 
      expected to increase every year, to pandemic proportions. These two pathologies 
      often coexist and have substantial public health implications. The term 
      "diabesity" defines the pathophysiological connection between overweight and 
      T2DM. The gut microbiota affects many aspects of the host. Beyond the regulation 
      of intestinal functions and the activation of immune responses, the gut 
      microbiota plays a role in central nervous system functions (i.e., mood, and 
      psychiatric conditions associated with stress and memory) and is a central 
      regulator of metabolism and appetite. RESULTS: The MGBA involves pathways such as 
      the autonomic and enteric nervous systems, the hypothalamic- pituitary-adrenal 
      axis, the immune system, enteroendocrine cells, and microbial metabolites. 
      Notably, the vagus nerve plays an essential role in eating behavior by modulating 
      appetite and learning nutritional preferences. CONCLUSIONS: Because of its 
      enteroendocrine cell-mediated interaction with the gut microbiota, the vagus 
      nerve may provide a potential pathway through which gut microorganisms influence 
      host feeding behavior and metabolic control of physiological and pathological 
      conditions.
CI  - (c) 2023. The Author(s).
FAU - Longo, Susanna
AU  - Longo S
AD  - Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 
      1, 00133, Rome, Italy.
FAU - Rizza, Stefano
AU  - Rizza S
AD  - Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 
      1, 00133, Rome, Italy.
FAU - Federici, Massimo
AU  - Federici M
AUID- ORCID: 0000-0003-4989-5194
AD  - Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 
      1, 00133, Rome, Italy. federicm@uniroma2.it.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230414
PL  - Germany
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
RN  - 121496-63-7 (methylglyoxal bis(3-aminopropylamidinohydrazone))
SB  - IM
MH  - Humans
MH  - *Gastrointestinal Microbiome/physiology
MH  - *Diabetes Mellitus, Type 2/metabolism
MH  - Brain-Gut Axis
MH  - Brain/metabolism
MH  - Obesity/metabolism
MH  - Vagus Nerve
PMC - PMC10289935
OTO - NOTNLM
OT  - Diabesity
OT  - Diabetes
OT  - GLP-1
OT  - Gut microbiota
OT  - Obesity
OT  - Vagus nerve
COIS- The authors report no conflicts of interest to disclose.
EDAT- 2023/04/15 06:00
MHDA- 2023/06/26 06:42
PMCR- 2023/04/14
CRDT- 2023/04/14 11:03
PHST- 2023/02/21 00:00 [received]
PHST- 2023/03/22 00:00 [accepted]
PHST- 2023/06/26 06:42 [medline]
PHST- 2023/04/15 06:00 [pubmed]
PHST- 2023/04/14 11:03 [entrez]
PHST- 2023/04/14 00:00 [pmc-release]
AID - 10.1007/s00592-023-02088-x [pii]
AID - 2088 [pii]
AID - 10.1007/s00592-023-02088-x [doi]
PST - ppublish
SO  - Acta Diabetol. 2023 Aug;60(8):1007-1017. doi: 10.1007/s00592-023-02088-x. Epub 
      2023 Apr 14.